Novartis's biggest sales growth drivers by change in sales 2019-2026
Inclisiran is expected to be one of the biggest sales growth drivers for Novartis with a total predicted change in sales of 2.22 billion U.S. dollars between 2019 and 2026. In the course of the COVID-19 pandemic, many pharma projects not related to SARS CoV-2 got delayed. On the other hand, drug approval agencies - like the FDA in the U.S. - are also focused on approvals of products related to the pandemic.